Camilla Krakstad's picture

Camilla Krakstad

  • E-mailCamilla.Krakstad@uib.no
  • Phone+47 55 97 67 97+47 992 54 140
  • Visitor Address
    Kvinneklinikken Haukeland University Hospital
    Department of Clinical Science
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2020. Tumour texture features from preoperative CT predict high-risk disease in endometrial cancer. Clinical Radiology. 1-8.
  • 2020. Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. European Radiology. 2443-2453.
  • 2020. Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers. 1-18.
  • 2020. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • 2020. Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer. 1014-1022.
  • 2019. Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer. 1037-1044.
  • 2019. Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. PLOS ONE. 1-13.
  • 2019. PIK3CA amplification associates with aggressive phenotype but not markers of AKT-mTOR signaling in endometrial carcinoma. Clinical Cancer Research. 334-345.
  • 2019. Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: A retrospective study. BMC Cancer. 1-8.
  • 2019. Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism.
  • 2019. Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecologic Oncology. 400-406.
  • 2019. Blood metabolites associate with prognosis in endometrial cancer. Metabolites. 1-15.
  • 2019. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Human Pathology. 90-98.
  • 2018. rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. International Journal of Molecular Sciences. 1-13.
  • 2018. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLOS ONE. 1-13.
  • 2018. Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. Journal of Magnetic Resonance Imaging. 1637-1647.
  • 2018. Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiologica. 1010-1017.
  • 2018. L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition. Virchows Archiv. 591-598.
  • 2018. Identification of nine new susceptibility loci for endometrial cancer. Nature Communications. 1-12.
  • 2018. Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • 2018. Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Medicine. 1978-1987.
  • 2018. Development of an image-guided orthotopic xenograft mouse model of endometrial cancer with controllable estrogen exposure. International Journal of Molecular Sciences. 1-16.
  • 2018. Blood steroids are associated with prognosis and fat distribution in endometrial cancer. Gynecologic Oncology. 46-52.
  • 2018. Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. Journal of Pathology. 203-214.
  • 2018. Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG: An International Journal of Obstetrics and Gynaecology. 1695-1703.
  • 2017. Type of vascular invasion in association with progress of endometrial cancer. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 1084-1091.
  • 2017. Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. OncoTarget. 109018-109026.
  • 2017. Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. OncoTarget. 106989-107001.
  • 2017. Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • 2017. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports. 1-12.
  • 2017. Increased microvascular permeability in mice lacking Epac1 (Rapgef3). Acta Physiologica. 441-452.
  • 2017. In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica. 497-505.
  • 2017. High visceral fat percentage is associated with poor outcome in endometrial cancer. OncoTarget. 105184-105195.
  • 2017. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • 2017. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology. 672-677.
  • 2017. Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. British Journal of Cancer. 840-847.
  • 2017. Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. OncoTarget. 3881-3894.
  • 2017. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. American Journal of Obstetrics and Gynecology. 432.e1-432.e17.
  • 2017. Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecologic Oncology. 197-203.
  • 2016. Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. OncoTarget. 69844-69856.
  • 2016. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • 2016. High mRNA levels of 17β-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer. Molecular and Cellular Endocrinology. 51-57.
  • 2016. Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility.
  • 2016. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. OncoTarget. 69097-69110.
  • 2016. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • 2016. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • 2015. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Molecular Oncology. 1694-1703.
  • 2015. Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 1574-1584.
  • 2015. Multimodal imaging of orthotopic mouse model of endometrial carcinoma. PLOS ONE. 11 pages.
  • 2015. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • 2015. Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma. Gynecologic Oncology. 529-537.
  • 2015. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics. 164-171.
  • 2015. Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics. 888-897.
  • 2015. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology. 542-548.
  • 2015. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology. 689-697.
  • 2015. Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLOS ONE.
  • 2015. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications.
  • 2015. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. International Journal of Cancer. 1863-1873.
  • 2015. ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • 2014. Switch in FOXA1 status associates with endometrial cancer progression. PLOS ONE.
  • 2014. Stathmin Protein Level, a Potential Peredictive Marker for Taxane Treatment Response in Endometrial Cancer. PLOS ONE.
  • 2014. Risk of ovarian cancer and the NF-kB pathway: Genetic association with IL1A and TNFSF10. Cancer Research. 852-861.
  • 2014. Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer.
  • 2014. Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. Pathology, Research and Practice. 774-778.
  • 2014. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. European Journal of Cancer. 3003-3010.
  • 2014. Landscape of genomic alterations in cervical carcinomas. Nature. 371-375.
  • 2014. Introduction of aromatic ring-containing substituents in cyclic nucleotides is associated with inhibition of toxin uptake by the hepatocyte transporters OATP 1B1 and 1B3. PLOS ONE.
  • 2014. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • 2014. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • 2014. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • 2014. Consortium analysis of diet-gene interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition & Food Research. 2023-2035.
  • 2013. Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 216-223.
  • 2013. Off-target effect of the Epac agonist 8-pCPT-2'-O-Me-cAMP on P2Y12 receptors in blood platelets. Biochemical and Biophysical Research Communications - BBRC. 603-608.
  • 2013. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics. 371-384.
  • 2013. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
  • 2013. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 pages.
  • 2013. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications. 12 pages.
  • 2013. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer. 3431-3441.
  • 2013. High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clinical Cancer Research. 2331-2341.
  • 2013. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics. 362-370.
  • 2013. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications. 10 pages.
  • 2013. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Modern Pathology. 428-434.
  • 2012. Loss of GPER identifies new targets for therapy among a subgroup of ER alpha-positive endometrial cancer patients with poor outcome. British Journal of Cancer. 1682-1688.
  • 2012. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer. 1997-2004.
  • 2012. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • 2012. Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention. 980-987.
  • 2011. Nostocyclopeptide-M1: A potent, nontoxic inhibitor of the hepatocyte drug transporters OATP1B3 and 1B1. Molecular Pharmaceutics. 360-367.
  • 2011. Cyclic AMP induces IPC leukemia cell apoptosis via CRE-and CDK-dependent Bim transcription. Cell Death and Differentiation. 11 pages.
  • 2009. Epac-induced Alterations in the Proteome of Human SH-SY5Y Neuroblastoma Cells. Journal of Proteomics & Bioinformatics. 244-245.
  • 2008. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • 2008. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 2866-2877.
  • 2006. CaM-kinasell-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. Cell Death and Differentiation. 1191-1202.
  • 2004. cAMP protects neutrophils against TNF?-induced apoptosis by activation of cAMP-dependent protein kinase, independently of exchange protein directly activated by cAMP (Epac). Journal of Leukocyte Biology. 641-647.
  • 2003. cAMP effector mechanisms. Novel twists for an "old" signaling system. FEBS Letters. 121-126.
  • 2003. Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells. Chemistry and Biology. 609-618.
  • 2002. Ca2+/calmodulin dependent protein kinase II is required for microcystin-induced apoptosis. Journal of Biological Chemistry. 2804-2811.
Academic lecture
  • 2004. cAMP protects neutrophils against TNFa-induced apoptosis by activation of cAMP-dependent protein kinase (cA-PK), independently of exchange protein directly activated by cAMP (Epac).
  • 2004. cAMP protects neutrophils against TNF_-induced apoptosis by activation of cAMP-dependent protein kinase (cA-PK), independently of exchange protein directly activated by cAMP (Epac).
  • 2004. Apoptotic phenotypes induced by natural toxins - Okadaic Acid acts by short-circuiting an ancient irradiation induced death pathway.
  • 2003. cAMP effector mechanisms. Novel twists for an "old" signalling system.
  • 2002. cAMP protects neutrophils against TNF_-induced apoptosis by activation of cAMP-dependent protein kinase (cA-PK), independently of exchange protein directly activated by cAMP (Epac).
  • 2001. Cell death in HeLa cells.
  • 1998. Distinct apoptotic death forms. Distinct pathways and functions?
Reader opinion piece
  • 2012. Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology. 516-519.
Masters thesis
  • 2008. Quantitative proteomics of Epac signaling in differentiating human SH-SY5Y neuroblastoma cells.
  • 2008. Epac-induced neuronal differentiation of Human SH-SY5Y neuroblastoma cells.
  • 2005. Role of Cu/Zn superoxide dismutase (SOD1) in phosphatase inhibitor-induced apoptosis.
Doctoral dissertation
  • 2018. Preclinical models and molecular biomarkers. Tools to improve treatment in endometrial carcinoma.
  • 2017. Molecular alterations suggesting new treatment strategies in uterine carcinomas.
  • 2016. Hormone signaling related factors as biomarkers in endometrial cancer.
  • 2005. The role of CaMKII and cA-PK in control of cell survival and death.
Academic chapter/article/Conference paper
  • 2013. PI3K Pathway in Gynecologic Malignancies.
  • 2007. Serine/Threonine Protein Phosphatases in Apoptosis. 16 pages.
  • 2013. FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 pages.
  • 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
  • 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. 18-18.
  • 2010. Liver specific transporters of microcystins as a tool to find novel inhibitors of OATP1B1 and OATP1B3.
  • 2003. Myeloid leukemia cell differentiation by bcl-2 and camp involves induction of ccaat/enhancer binding protein ? (c/ebp?), nuclear accumulation of c/ebp?, and direct interaction between bcl-2 and c/ebp?
  • 2002. Effects of a new bioactive substance from a marine microalga on mammalian cells.
Academic literature review
  • 2020. Improving response to progestin treatment of low-grade endometrial cancer. .
  • 2019. Imaging of preclinical endometrial cancer models for monitoring tumor progression and response to targeted therapy. 1-16.
  • 2018. Patient-derived xenograft models for endometrial cancer research. 1-17.
  • 2018. Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer.
  • 2016. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 386-401.
  • 2011. The cAMP-dependent protein kinase pathway as therapeutic target - possibilities and pitfalls. 1393-1405.
  • 2010. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. 135 .

More information in national current research information system (CRIStin)